176 related articles for article (PubMed ID: 36592369)
1. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) on the Outcomes of Patients With Metastatic Pancreatic Adenocarcinoma (MPA) During First-Line Treatment With FOLFIRINOX: A Single-Center Retrospective Analysis.
Carvalho de Brito AB; Riechelmann RP; Fonseca de Jesus VH
Cancer Control; 2023; 30():10732748221149543. PubMed ID: 36592369
[TBL] [Abstract][Full Text] [Related]
2. Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.
Canton C; Boussari O; Boulin M; Le Malicot K; Taieb J; Dahan L; Lopez A; Lepage C; Bachet JB
Oncologist; 2022 Jul; 27(7):e571-e579. PubMed ID: 35289915
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.
Terazawa T; Goto M; Miyamoto T; Asaishi K; Shimamoto F; Kuwakado S; Nishitani H; Kii T; Higuchi K
Intern Med; 2015; 54(23):2969-73. PubMed ID: 26631878
[TBL] [Abstract][Full Text] [Related]
4. [Two cases of pancreatic cancer treated with FOLFIRINOX regimen and G-CSF prophylaxis at the standard therapeutic dose].
Kiba T; Okada Y; Kajiume S; Yamaguchi A
Gan To Kagaku Ryoho; 2015 May; 42(5):629-32. PubMed ID: 25981661
[TBL] [Abstract][Full Text] [Related]
5. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
Lee JC; Kim JW; Ahn S; Kim HW; Lee J; Kim YH; Paik KH; Kim J; Hwang JH
Eur J Cancer; 2017 May; 76():125-133. PubMed ID: 28324747
[TBL] [Abstract][Full Text] [Related]
6. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z
Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375
[TBL] [Abstract][Full Text] [Related]
7. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy.
Gawade PL; Li S; Henry D; Smith N; Belani R; Kelsh MA; Bradbury BD
Support Care Cancer; 2020 Sep; 28(9):4413-4424. PubMed ID: 31919669
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice.
Almenar Cubells D; Bosch Roig C; Jiménez Orozco E; Álvarez R; Cuervo JM; Díaz Fernández N; Sánchez Heras AB; Galán Brotons A; Giner Marco V; Codes M De Villena M;
Eur J Cancer Care (Engl); 2013 May; 22(3):400-12. PubMed ID: 23331323
[TBL] [Abstract][Full Text] [Related]
9. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
Schenfeld J; Gong T; Henry D; Kelsh M; Gawade P; Peng Y; Bradbury BD; Li S
Support Care Cancer; 2022 Jul; 30(7):6327-6338. PubMed ID: 35482126
[TBL] [Abstract][Full Text] [Related]
10. Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study.
Yamao K; Takenaka M; Yoshikawa T; Ishikawa R; Okamoto A; Yamazaki T; Nakai A; Omoto S; Kamata K; Minaga K; Hagiwara S; Sakurai T; Nishida N; Chiba Y; Watanabe T; Kudo M
Intern Med; 2019 Jul; 58(14):1993-2002. PubMed ID: 30996164
[TBL] [Abstract][Full Text] [Related]
11. G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans.
Cardot-Ruffino V; Bollenrucher N; Delius L; Wang SJ; Brais LK; Remland J; Keheler CE; Sullivan KM; Abrams TA; Biller LH; Enzinger PC; McCleary NJ; Patel AK; Rubinson DA; Schlechter B; Slater S; Yurgelun MB; Cleary JM; Perez K; Dougan M; Ng K; Wolpin BM; Singh H; Dougan SK
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344102
[TBL] [Abstract][Full Text] [Related]
12. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.
Barnes G; Pathak A; Schwartzberg L
Adv Ther; 2014 Jul; 31(7):683-95. PubMed ID: 24989316
[TBL] [Abstract][Full Text] [Related]
15. The impact of granulocyte colony-stimulating factor use in patients with metastatic breast cancer treated with palliative chemotherapy: a single-institution retrospective review.
Mousa L; Stephens JA; Berger M; Ramaswamy B; Lustberg M; Sardesai S; Williams N; VanDeusen J; Stover D; Cherian M; Morgan E; Wesolowski R
Support Care Cancer; 2020 Nov; 28(11):5537-5545. PubMed ID: 32185556
[TBL] [Abstract][Full Text] [Related]
16. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.
Gerlier L; Lamotte M; Awada A; Bosly A; Bries G; Cocquyt V; Focan C; Henry S; Lalami Y; Machiels JP; Mebis J; Straetmans N; Verhoeven D; Somers L
BMC Cancer; 2010 Nov; 10():642. PubMed ID: 21092320
[TBL] [Abstract][Full Text] [Related]
17. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
Agiro A; Ma Q; Acheson AK; Wu SJ; Patt DA; Barron JJ; Malin JL; Rosenberg A; Schilsky RL; Lyman GH
J Clin Oncol; 2016 Nov; 34(32):3872-3879. PubMed ID: 27646945
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
[TBL] [Abstract][Full Text] [Related]
19. Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment.
Jung JH; Shin DW; Kim J; Lee JC; Hwang JH
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33120908
[TBL] [Abstract][Full Text] [Related]
20. [Cost-effectiveness of primary prophylaxis with PEG-rhG-CSF in early-stage breast cancer patients receiving chemotherapy in China].
Xia W; Wang SS; Hu H; Zhao FL; Xu F; Hong RX; Jiang KK; Yuan ZY; Shi YX; Zhao K; Huang JJ; Xue C; Bi XW; Lu QY; An X; Zhang JM
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):861-867. PubMed ID: 33113628
[No Abstract] [Full Text] [Related]
[Next] [New Search]